SNF.Back to Emerging
Emerging Detail

ADRX - ADARx Pharmaceuticals, Inc.

Candidate

SNF Emerging Watchlist(TM) tracks newly public companies positioned around emerging economic themes. Inclusion reflects SNF research interest and ongoing monitoring; it is not a recommendation to buy, sell, or hold a security.

Emerging Score
83 / 100
Confidence
93%
Band
Strong Emerging Profile
Last Reviewed
Oct 23, 2026
Primary Theme
Biotechnology / Health Innovation
Exchange
Nasdaq
Current Thesis

Structural Theme Relevance

What Changed

Candidate to Candidate review completed.

Why It Matters

Structural Theme Relevance

What The Market Is Pricing In

Market Confirmation currently scores 50/100 within the Emerging Score framework.

What Could Change The Narrative

Phase 3 STOP-HAE execution and clinical readout risk

SNF Lens
Signal
Structural Theme Relevance
Noise
Some evidence needs refresh context.
Confirmation
Market Confirmation 50/100
Risk
Phase 3 STOP-HAE execution and clinical readout risk
Six-Family Scorecard
Structural Theme Relevance
88
Business Quality
86
Growth / Traction
91
Competitive Position
88
Financial Durability
86
Market Confirmation
50
Key Risks
Phase 3 STOP-HAE execution and clinical readout risk
Clinical-stage cash burn, competition and regulatory execution
Evidence Quality
Active Evidence
6
Sources
3
Stale Evidence
1
Freshness
Mixed freshness
Review / Score History
Oct 23, 2026Thesis unchanged - Candidate unchanged
Oct 4, 2026Thesis strengthened - Candidate unchanged
Oct 23, 2026Score 83 / Confidence 93 / Candidate
Oct 4, 2026Score 83 / Confidence 93 / Candidate
Sources
sec.gov
sec-filing - Sep 24, 2026
Open source
investors.adarx.com
company-ir - Sep 24, 2026
Open source
stockanalysis.com
market-data - Oct 4, 2026
Open source